Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

[Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].

Zhang Y, Xiao C, Gu SC, Chang CK.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1027-32. doi: 10.7534/j.issn.1009-2137.2014.04.026. Chinese.

PMID:
25130822
2.

[Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].

Qin Y, Liu H, Ruan S, Cai YF, You XF, Song GQ.

Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):758-61. Chinese.

PMID:
22339912
3.

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.

Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G; IRON-2 Study Group..

Ann Hematol. 2015 May;94(5):779-87. doi: 10.1007/s00277-014-2274-y. Epub 2014 Dec 18.

PMID:
25516455
4.

[Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload].

Gu CH, Li CX, Ye L, Liu H, Ma JF, Wang T, Zou Q, Chen J, Chen XC, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2016 Mar;37(3):189-93. doi: 10.3760/cma.j.issn.0253-2727.2016.03.003. Chinese.

PMID:
27033754
5.

[Clinical study of iron metabolism indicators in ineffective hematopoiesis of myelodysplastic syndrome].

Yang Y, Yang B, Liang ZP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):948-52. doi: 10.7534/j.issn.1009-2137.2013.04.026. Chinese.

PMID:
23998591
6.

Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Leitch HA.

Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000. Review.

PMID:
21275444
7.

Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.

Merkel DG, Nagler A.

Expert Rev Anticancer Ther. 2014 Jul;14(7):817-29. doi: 10.1586/14737140.2014.896208. Epub 2014 Mar 18. Review.

PMID:
24641787
8.

The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.

Gu S, Song X, Zhao Y, Guo J, Fei C, Xu F, Wu L, Zhang X, Zhao J, Chang C, Li X.

Hematology. 2013 Sep;18(5):286-94. doi: 10.1179/1607845412Y.0000000064. Epub 2013 Mar 20.

PMID:
23540794
9.

Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.

Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N.

Leuk Res. 2012 Aug;36(8):1067-70. doi: 10.1016/j.leukres.2012.04.006. Epub 2012 May 6.

PMID:
22564985
10.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
11.

Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.

Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S.

Saudi J Kidney Dis Transpl. 2015 Jan;26(1):19-25.

12.

Iron chelation therapy in MDS: what have we learnt recently?

Schmid M.

Blood Rev. 2009 Dec;23 Suppl 1:S21-5. doi: 10.1016/S0268-960X(09)70006-2. Review.

PMID:
20116636
13.

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.

Ann Hematol. 2010 Feb;89(2):147-54. doi: 10.1007/s00277-009-0794-7. Epub 2009 Aug 19.

PMID:
19690857
14.

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.

Free Radic Biol Med. 2012 Aug 15;53(4):643-8. doi: 10.1016/j.freeradbiomed.2012.06.006. Epub 2012 Jun 15.

PMID:
22705364
15.

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.

Breccia M, Voso MT, Aloe Spiriti MA, Fenu S, Maurillo L, Buccisano F, Tafuri A, Alimena G.

Ann Hematol. 2015 May;94(5):771-7. doi: 10.1007/s00277-015-2341-z. Epub 2015 Mar 7. Review.

PMID:
25743685
16.
17.

Endogenous erythropoietin levels and anemia in long-term renal transplant recipients.

Zadrazil J, Horák P, Horcicka V, Zahálková J, Strébl P, Hrubý M.

Kidney Blood Press Res. 2007;30(2):108-16. Epub 2007 Mar 19.

18.

Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.

Leuk Res. 2014 May;38(5):545-50. doi: 10.1016/j.leukres.2014.01.016. Epub 2014 Feb 10.

19.

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.

Ann Hematol. 2011 Jun;90(6):655-66. doi: 10.1007/s00277-011-1164-9. Epub 2011 Feb 12.

PMID:
21318574
20.

The role of iron chelation therapy for patients with myelodysplastic syndromes.

Steensma DP.

J Natl Compr Canc Netw. 2011 Jan;9(1):65-75. Review.

PMID:
21233245

Supplemental Content

Support Center